指南与共识中毒与环境急症

美国医学毒理学会与美国临床毒理学会立场声明:纳美芬目前不应取代纳洛酮作为主要阿片类解毒剂

American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time.
指南 / 共识 · Clin Toxicol (Phila) · 2023-12-19
一句话结论美国医学毒理学会与美国临床毒理学会认为,纳美芬未在当前合成阿片类过量环境中验证且可能延长戒断,目前不应取代纳洛酮作为主要阿片类解毒剂。

纳美芬是强效阿片受体拮抗剂,注射剂型2008年撤市后于2022年重新引入,2023年美国食品药品监督管理局通过简化新药申请批准其鼻喷剂型,未要求新的临床数据,因此鼻喷纳美芬未在正发生阿片类过量的患者中研究。纳美芬对阿片受体亲和力高于纳洛酮且作用时间更长,但两者比较有效性数据稀少,且已有证据提示纳美芬可能比纳洛酮导致更持久、更严重的阿片戒断,可能对患者有害。美国医学毒理学会与美国临床毒理学会认为,纳美芬未在当前合成阿片类过量临床环境中验证且可能因延长戒断造成伤害,目前不应取代纳洛酮作为主要阿片类解毒剂。声明推荐在推荐纳美芬作为主要阿片类解毒剂之前,应以所有已批准给药途径开展纳美芬与纳洛酮的比较性临床研究并评估安全性和有效性结局。

要点

  • 美国医学毒理学会与美国临床毒理学会认为,纳美芬目前不应取代纳洛酮作为主要阿片类解毒剂。
  • 鼻喷纳美芬2023年通过简化新药申请获批,未要求新的临床数据,未在正发生阿片类过量的患者中研究。
  • 纳美芬对阿片受体亲和力高于纳洛酮且作用时间更长,但两者比较有效性数据稀少。
  • 已有证据提示纳美芬可能比纳洛酮导致更持久、更严重的阿片戒断,可能对患者有害。
  • 声明推荐在推荐纳美芬作为主要阿片类解毒剂之前,以所有已批准给药途径开展纳美芬与纳洛酮的比较性临床研究并评估安全性和有效性结局。

适用人群与场景

  • 已知或疑似阿片类过量的患者(纳美芬在美国获批用于治疗已知或疑似阿片类过量)。

红旗征与不能漏的情况

  • 纳美芬可能比纳洛酮导致更持久、更严重的阿片戒断,可能对患者有害。

研究设计与关键结果

  • 纳美芬注射剂型2008年撤市后于2022年重新引入,2023年美国食品药品监督管理局批准新的鼻喷纳美芬剂型。
  • 因纳美芬1995年已通过注射途径获批,鼻喷剂型以简化新药申请获批,未要求新的临床数据,未在正发生阿片类过量的患者中研究。
  • 纳美芬对阿片受体亲和力高于纳洛酮且作用时间更长;两者比较有效性数据稀少,纳美芬的固有特性在阿片类过量中是否有益尚不清楚。
  • 已有数十年安全有效使用纳洛酮作为主要阿片类解毒剂的经验,包括芬太尼及芬太尼类似物过量。
  • 已有证据提示纳美芬可能比纳洛酮导致更持久、更严重的阿片戒断。

证据类型、等级与局限

  • 证据类型:美国医学毒理学会与美国临床毒理学会立场声明。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 美国医学毒理学会与美国临床毒理学会认为,纳美芬目前不应取代纳洛酮作为主要阿片类解毒剂。
  • 声明推荐在推荐纳美芬作为主要阿片类解毒剂之前,以所有已批准给药途径开展纳美芬与纳洛酮的比较性临床研究,并评估安全性和有效性结局。

指南或共识出处

  • 美国医学毒理学会与美国临床毒理学会立场声明:纳美芬目前不应取代纳洛酮作为主要阿片类解毒剂(发表于 Clinical Toxicology (Phila))。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Nalmefene is a potent opioid antagonist that has recently been reintroduced in the United States to treat known or suspected opioid overdose.

NALMEFENE CLINICAL TRIAL DATA: The injection formulation, which had been withdrawn in 2008, was reintroduced in 2022, and in 2023 the United States Food and Drug Administration approved a new intranasal formulation of nalmefene. Because nalmefene had been previously approved for use in 1995 via injection, the new intranasal formulation did not require new clinical data as it was approved under an Abbreviated New Drug Application. Inherent to this abbreviated approval process, intranasal nalmefene was not studied in patients currently suffering opioid overdose.

NALOXONE AND NALMEFENE: Nalmefene also has unique characteristics compared with naloxone, the current standard opioid antidote. Nalmefene has a higher affinity for opioid receptors and a longer duration of action than naloxone. Comparative effectiveness data regarding naloxone and nalmefene are sparse, and it is unclear if the inherent properties of nalmefene are beneficial in opioid overdose. We have decades of experience using naloxone safely and effectively as the primary opioid antidote, even in cases of fentanyl and fentanyl analog overdoses. There is, however, evidence to suggest nalmefene may result in more prolonged and severe opioid withdrawal than naloxone, which could be harmful to patients.

POSITION: As nalmefene is untested in the current clinical environment of synthetic opioid overdoses and has the potential to cause harm via prolonged withdrawal, it is the opinion of the American College of Medical Toxicology and the American Academy of Clinical Toxicology that nalmefene should not replace naloxone as the primary opioid antidote at this time.

RECOMMENDATIONS: We recommend additional clinical studies of nalmefene, administered via all approved routes, be conducted in a comparative fashion with naloxone, and that safety and effectiveness outcomes be evaluated before nalmefene is recommended as a primary opioid antidote.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Stolbach AI, Mazer-Amirshahi ME, Nelson LS, et al. American College of Medical Toxicology and the American Academy of Clinical Toxicology position statement: nalmefene should not replace naloxone as the primary opioid antidote at this time. Clin Toxicol (Phila). 2023. PMID: 38039052. doi:10.1080/15563650.2023.2283391

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。